Q-omics provides the consensus-scored QPCTL profile across patient tissues and cancer cell-line models. QPCTL expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, QPCTL is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, QPCTL RNA expression shows 17,734 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KIRC, and ACC as cancer lineages where QPCTL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for QPCTL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes QPCTL survival associations across molecular data types. QPCTL RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible QPCTL RNA expression–survival associations across cancer types. High QPCTL expression shows unfavorable associations in MESO, ACC, KIRP, LGG, SKCM and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for QPCTL RNA expression.
This table summarizes QPCTL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for QPCTL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. QPCTL shows higher tumor expression in KIRC, KIRP, HNSC, COAD, LIHC and BLCA. The KIRC box plot shows higher QPCTL RNA expression in tumor versus normal tissue (log2 FC = +1.008, t-test p < 0.001).
This table shows molecular features associated with QPCTL in patient tissues and cancer cell lines. In patient samples, QPCTL shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, QPCTL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Lymphoma.
